VIENNA, 19 December 2018 – UNIDO’s pharmaceutical team has published the latest in a series of papers designed to support the planning and development of commercially viable and sustainable vaccine manufacturing facilities. The aim of the paper is to introduce entities such as policymakers and entrepreneurs to some of the basic processes and analytical tools that help them to identify and understand commercially viable vaccine manufacturing opportunities in developing countries.
This latest paper, “Commercialising vaccines: A methodology to identify potential market opportunities and conduct outline assessments” compliments UNIDO’s 2017 publication that examined key factors and cost drivers relevant to the setting up of new facilities, “Establishing Manufacturing Capabilities for Human Vaccines”.
The paper describes a three step process designed to analyse a country market, in this case taking South Africa as an example. The first step involves an analysis of current vaccine needs and supply, and is followed by the identification of individual vaccines where local production may be financially viable. The output of this second analysis is then fed into the third step which assesses the feasibility of local production and takes into account the practicalities of vaccine manufacture.
Click here to read the full paper.
For more information: Mr. Martin Nicholson (M.Nicholson [at] unido.org)